Lytix Biopharma AS: Annual Report for 2025

24 Mar 2026 07:03 CET

Oslo, Norway, March 24, 2026 – Lytix Biopharma AS (“Lytix”) (Euronext Growth
Oslo: LYTIX), a clinical-stage immuno-oncology company, has today published its
Annual Report for 2025, which was approved by the board of directors on March
23, 2026.

2025 marked a defining year for Lytix, with continued clinical progress,
important strategic advancements, and a clearer pathway toward late-stage
development and commercialization of its lead candidate, ruxotemitide (formerly
LTX-315).

“2025 has been a defining year for Lytix Biopharma,” said Øystein Rekdal, CEO of
Lytix Biopharma. “We have strengthened the clinical foundation of our technology
platform through multiple Phase II studies, including encouraging interim
results from the NeoLIPA study in neoadjuvant melanoma. At the same time, our
partner Verrica has continued to advance the basal cell carcinoma program toward
Phase III, supported by new immune-response data. Combined with a more focused
strategy and strengthened organization, this positions Lytix for the next phase
of development as we work toward commercialization and strategic partnerships.”

During the year, Lytix reported positive interim data from the NeoLIPA Phase II
study, demonstrating a 44% pathological complete response rate and an overall
pathological response of approximately 90% among the first evaluable patients.
In parallel, the ATLAS-IT-05 study in advanced melanoma confirmed systemic
immune activation and durable disease control in a heavily pretreated patient
population.

The company also continued to support its partner Verrica Pharmaceuticals in
advancing ruxotemitide toward a potential Phase III program in basal cell
carcinoma, while progressing preparations for clinical entry of its
next-generation candidate, LTX-401.

Following the reporting period, Lytix strengthened its financial position
through a private placement and subsequent offering raising total gross proceeds
of approximately NOK 77.3 million, providing financial flexibility to advance
its development programs.

The Annual Report for 2025 is attached to this notice and is also available on
the company’s website, www.lytixbiopharma.com, under Investors.

For further information, please contact:
Gjest Breistein, CFO
E-mail: gjest.breistein@lytixbiopharma.com
Phone: +47 952 60 512

About Lytix Biopharma
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company
developing novel immunotherapies based on oncolytic peptides that directly kill
tumor cells and activate the immune system to target solid tumors. The company’s
lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic
molecule being evaluated across multiple cancer indications and treatment
settings, both as monotherapy and in combination with immune checkpoint
inhibitors.

More information:
Access the news on Oslo Bors NewsWeb site

669137_2025 Lytix - Annual Report - Final 2023-03-23.pdf